Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Funahashi

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Neuron|January 26, 2016
Phosphoproteomics of the Dopamine Pathway Enables Discovery of Rap1 Activation as a Reward Signal In VivoTaku Nagai, Shinichi Nakamuta, Keisuke Kuroda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Vascular Cell|September 9, 2014
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageYuji Yamamoto, Junji Matsui, Tomohiro Matsushima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyRichard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Science Signaling|September 10, 2024
Signal flow in the NMDA receptor-dependent phosphoproteome regulates postsynaptic plasticity for aversive learningYasuhiro Funahashi, Rijwan Uddin Ahammad, Xinjian Zhang, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Cancer Research Communications|July 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Cancer Research|January 7, 2021
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt SignalingKazuhiko Yamada, Yusaku Hori, Satoshi Inoue, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Neuron|January 26, 2016
Phosphoproteomics of the Dopamine Pathway Enables Discovery of Rap1 Activation as a Reward Signal In VivoTaku Nagai, Shinichi Nakamuta, Keisuke Kuroda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Vascular Cell|September 9, 2014
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageYuji Yamamoto, Junji Matsui, Tomohiro Matsushima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyRichard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Science Signaling|September 10, 2024
Signal flow in the NMDA receptor-dependent phosphoproteome regulates postsynaptic plasticity for aversive learningYasuhiro Funahashi, Rijwan Uddin Ahammad, Xinjian Zhang, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Cancer Research Communications|July 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Cancer Research|January 7, 2021
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt SignalingKazuhiko Yamada, Yusaku Hori, Satoshi Inoue, et al.
Pageof 13